Cancers (Jul 2020)
Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe
- David J. Pinato,
- Alvin J. X. Lee,
- Federica Biello,
- Elia Seguí,
- Juan Aguilar-Company,
- Anna Carbó,
- Riccardo Bruna,
- Mark Bower,
- Gianpiero Rizzo,
- Sarah Benafif,
- Carme Carmona,
- Neha Chopra,
- Claudia Andrea Cruz,
- Francesca D’Avanzo,
- Joanne S. Evans,
- Myria Galazi,
- Isabel Garcia-Fructuoso,
- Alessia Dalla Pria,
- Thomas Newsom-Davis,
- Diego Ottaviani,
- Andrea Patriarca,
- Roxana Reyes,
- Rachel Sharkey,
- Christopher C. T. Sng,
- Yien Ning Sophia Wong,
- Daniela Ferrante,
- Lorenza Scotti,
- Gian Carlo Avanzi,
- Mattia Bellan,
- Luigi Mario Castello,
- Javier Marco-Hernández,
- Meritxell Mollà,
- Mario Pirisi,
- Isabel Ruiz-Camps,
- Pier Paolo Sainaghi,
- Gianluca Gaidano,
- Joan Brunet,
- Josep Tabernero,
- Aleix Prat,
- Alessandra Gennari
Affiliations
- David J. Pinato
- Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London W12 0HS, UK
- Alvin J. X. Lee
- Department of Oncology, University College London Hospitals, London NW1 2PG, UK
- Federica Biello
- Department of Translational Medicine, Division of Oncology, University of Piemonte Orientale and Maggiore della Carita’ Hospital, 28100 Novara, Italy
- Elia Seguí
- Department of Medical Oncology, Hospital Clinic, 08036 Barcelona, Spain
- Juan Aguilar-Company
- Department of Medical Oncology, Vall d’Hebron University Hospital and Institute of Oncology (VHIO), 08035 Barcelona, Spain
- Anna Carbó
- Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, 17007 Girona, Spain
- Riccardo Bruna
- Department of Translational Medicine, Division of Haematology, University of Piemonte Orientale and Maggiore della Carita’ Hospital, 28100 Novara, Italy
- Mark Bower
- Department of Oncology and National Centre for HIV Malignancy, Chelsea & Westminster Hospital, London SW109NH, UK
- Gianpiero Rizzo
- Department of Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
- Sarah Benafif
- Department of Oncology, University College London Hospitals, London NW1 2PG, UK
- Carme Carmona
- Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, 17007 Girona, Spain
- Neha Chopra
- Department of Oncology, University College London Hospitals, London NW1 2PG, UK
- Claudia Andrea Cruz
- Department of Medical Oncology, Hospital Clinic, 08036 Barcelona, Spain
- Francesca D’Avanzo
- Department of Translational Medicine, Division of Oncology, University of Piemonte Orientale and Maggiore della Carita’ Hospital, 28100 Novara, Italy
- Joanne S. Evans
- Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London W12 0HS, UK
- Myria Galazi
- Department of Oncology, University College London Hospitals, London NW1 2PG, UK
- Isabel Garcia-Fructuoso
- Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, 17007 Girona, Spain
- Alessia Dalla Pria
- Department of Oncology and National Centre for HIV Malignancy, Chelsea & Westminster Hospital, London SW109NH, UK
- Thomas Newsom-Davis
- Department of Oncology and National Centre for HIV Malignancy, Chelsea & Westminster Hospital, London SW109NH, UK
- Diego Ottaviani
- Department of Oncology, University College London Hospitals, London NW1 2PG, UK
- Andrea Patriarca
- Department of Translational Medicine, Division of Haematology, University of Piemonte Orientale and Maggiore della Carita’ Hospital, 28100 Novara, Italy
- Roxana Reyes
- Department of Medical Oncology, Hospital Clinic, 08036 Barcelona, Spain
- Rachel Sharkey
- Department of Translational Medicine, Division of Haematology, University of Piemonte Orientale and Maggiore della Carita’ Hospital, 28100 Novara, Italy
- Christopher C. T. Sng
- Department of Oncology, University College London Hospitals, London NW1 2PG, UK
- Yien Ning Sophia Wong
- Department of Oncology, University College London Hospitals, London NW1 2PG, UK
- Daniela Ferrante
- Department of Translational Medicine, Unit of Cancer Epidemiology, CPO-Piemonte, University of Piemonte Orientale, 28100 Novara, Italy
- Lorenza Scotti
- Department of Translational Medicine, University of Piemonte Orientale and Maggiore della Carita’ Hospital, 28100 Novara, Italy
- Gian Carlo Avanzi
- Department of Translational Medicine, Divisions of Internal and Emergency Medicine, University of Piemonte Orientale and Maggiore della Carita’ Hospital, 28100 Novara, Italy
- Mattia Bellan
- Department of Translational Medicine, Divisions of Internal and Emergency Medicine, University of Piemonte Orientale and Maggiore della Carita’ Hospital, 28100 Novara, Italy
- Luigi Mario Castello
- Department of Translational Medicine, Divisions of Internal and Emergency Medicine, University of Piemonte Orientale and Maggiore della Carita’ Hospital, 28100 Novara, Italy
- Javier Marco-Hernández
- Department of Internal Medicine, Hospital Clinic, 08035 Barcelona, Spain
- Meritxell Mollà
- Department of Radiation Oncology, Hospital Clinic, 08035 Barcelona, Spain
- Mario Pirisi
- Department of Translational Medicine, Divisions of Internal and Emergency Medicine, University of Piemonte Orientale and Maggiore della Carita’ Hospital, 28100 Novara, Italy
- Isabel Ruiz-Camps
- Department of Infectious Diseases, Vall d’Hebron University Hospital, 08035 Barcelona, Spain
- Pier Paolo Sainaghi
- Department of Translational Medicine, Divisions of Internal and Emergency Medicine, University of Piemonte Orientale and Maggiore della Carita’ Hospital, 28100 Novara, Italy
- Gianluca Gaidano
- Department of Translational Medicine, Division of Haematology, University of Piemonte Orientale and Maggiore della Carita’ Hospital, 28100 Novara, Italy
- Joan Brunet
- Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, 17007 Girona, Spain
- Josep Tabernero
- Department of Medical Oncology, Vall d’Hebron University Hospital and Institute of Oncology (VHIO), 08035 Barcelona, Spain
- Aleix Prat
- Department of Medical Oncology, Hospital Clinic, 08036 Barcelona, Spain
- Alessandra Gennari
- Department of Translational Medicine, Division of Oncology, University of Piemonte Orientale and Maggiore della Carita’ Hospital, 28100 Novara, Italy
- DOI
- https://doi.org/10.3390/cancers12071841
- Journal volume & issue
-
Vol. 12,
no. 7
p. 1841
Abstract
We describe the outcomes in cancer patients during the initial outbreak of the COVID-19 in Europe from the retrospective, multi-center observational OnCovid study. We identified 204 cancer patients from eight centers in the United Kingdom, Italy, and Spain aged >18 (mean = 69) and diagnosed with COVID-19 between 26 February and 1 April 2020. A total of 127 (62%) were male, 184 (91%) had a diagnosis of solid malignancy, and 103 (51%) had non-metastatic disease. A total of 161 (79%) had >1 co-morbidity. A total of 141 (69%) patients had >1 COVID-19 complication. A total of 36 (19%) were escalated to high-dependency or intensive care. A total of 59 (29%) died, 53 (26%) were discharged, and 92 (45%) were in-hospital survivors. Mortality was higher in patients aged >65 (36% vs. 16%), in those with >2 co-morbidities (40% vs. 18%) and developing >1 complication from COVID-19 (38% vs. 4%, p = 0.004). Multi-variable analyses confirmed age > 65 and >2 co-morbidities to predict for patient mortality independent of tumor stage, active malignancy, or anticancer therapy. During the early outbreak of SARS-CoV-2 infection in Europe co-morbid burden and advancing age predicted for adverse disease course in cancer patients. The ongoing OnCovid study will allow us to compare risks and outcomes in cancer patients between the initial and later stages of the COVID-19 pandemic.
Keywords
